Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study

Background and Aim: Mild cognitive impairment (MCI) is characterized by declined cognitive function greater than that expected for a person’s age. The clinical significance of this condition is its possible progression to dementia. MLC601 is a natural neuroprotective medication that has shown promis...

Full description

Bibliographic Details
Main Authors: Hossein Pakdaman, Ali Amini Harandi, Mehdi Abbasi, Hosein Delavar Kasmaei, Farzad Ashrafi, Koroush Gharagozli, Farhad Assarzadegan, Behdad Behnam, Mehran Arabahmadi
Format: Article
Language:English
Published: Karger Publishers 2017-05-01
Series:Dementia and Geriatric Cognitive Disorders Extra
Subjects:
Mild cognitive impairment
MLC601
Placebo-controlled study
Double-blind study
Safety

Online Access:http://www.karger.com/Article/FullText/458521

Internet

http://www.karger.com/Article/FullText/458521

Similar Items